APTX.TO
Apotex Health Corp.
TorontoCADEQUITY
DELAYED
Last price
33.87
▲ 0.48 (1.44%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
33.39
Prev close
33.39
Day high
34.05
Day low
32.73
Volume
194.97K
Market cap
—
P/E (TTM)
—
52W range
26.05 – 40.18
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-0.82%
+0.5%
1M
-7.33%
-11.1%
3M
—
-3.1%
6M
—
-11.1%
YTD
+25.44%
+13.2%
1Y
—
-20.0%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | YoY |
|---|---|---|---|---|
| Total revenue | $3.49B | $3.35B | $2.94B | +4.2% |
| Operating revenue | $3.49B | $3.35B | $2.94B | +4.2% |
| Cost of revenue | $1.55B | $1.56B | $1.84B | -0.4% |
| Gross profit | $1.94B | $1.79B | $1.10B | +8.2% |
| Research & development | $162.61M | $216.04M | $173.08M | -24.7% |
| Selling, general & admin | $528.22M | $487.16M | $463.69M | +8.4% |
| Total operating expense | $902.78M | $1.03B | $909.18M | -12.2% |
| Operating income | $1.04B | $765.76M | $194.19M | +35.7% |
| Net interest income | -$260.56M | -$216.81M | -$158.54M | -20.2% |
| Pre-tax income | $519.87M | $310.63M | -$155.56M | +67.4% |
| Tax provision | $146.09M | $158.93M | -$8.64M | -8.1% |
| Net income | $373.78M | $151.70M | -$146.92M | +146.4% |
| Net income to common | $373.78M | $151.70M | -$146.92M | +146.4% |
| Basic EPS | — | 0.66 | -0.64 | — |
| Diluted EPS | — | 0.66 | -0.64 | — |
| EBIT | $762.38M | $531.50M | $11.16M | +43.4% |
| EBITDA | $911.77M | $668.03M | $161.91M | +36.5% |
| Basic shares | — | 228.50M | 228.50M | — |
| Diluted shares | — | 228.50M | 228.50M | — |
| Line item | 2026 | 2025 | 2024 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $56.99M | $77.97M | $421.35M | -26.9% |
| Cash & short-term investments | $56.99M | $77.97M | $421.35M | -26.9% |
| Accounts receivable | $820.46M | $876.02M | $721.07M | -6.3% |
| Inventory | $930.04M | $973.57M | $832.20M | -4.5% |
| Total current assets | $2.17B | $2.32B | $2.44B | -6.5% |
| Property, plant & equipment | $1.13B | $1.14B | $1.11B | -1.0% |
| Goodwill & intangibles | $1.05B | $1.06B | $214.25M | -0.7% |
| Total assets | $4.54B | $4.85B | $4.04B | -6.3% |
| Total current liabilities | $1.45B | $1.67B | $1.34B | -13.1% |
| Current debt | $101.21M | $108.42M | $34.69M | -6.7% |
| Long-term debt | $2.84B | $1.96B | $1.29B | +44.9% |
| Total debt | $3.52B | $2.65B | $1.87B | +32.9% |
| Total liabilities | $5.10B | $4.56B | $3.31B | +11.9% |
| Retained earnings | -$967.05M | -$231.21M | -$218.95M | -318.3% |
| Shareholder equity | -$557.93M | $290.59M | $732.53M | -292.0% |
| Working capital | $724.68M | $655.40M | $1.11B | +10.6% |
| Net tangible assets | -$1.61B | -$770.94M | $518.28M | -109.1% |
| Shares issued | 231.73M | 231.73M | 231.73M | 0.0% |
| Line item | 2026 | 2025 | 2024 | YoY |
|---|---|---|---|---|
| Net income | $373.78M | $151.70M | -$146.92M | +146.4% |
| Depreciation & amortisation | $149.40M | $136.54M | $150.75M | +9.4% |
| Stock-based compensation | $64.65M | $73.48M | $53.48M | -12.0% |
| Change in working capital | $101.34M | $112.10M | $372.01M | -9.6% |
| Operating cash flow | $640.96M | $554.41M | $570.90M | +15.6% |
| Capital expenditure | -$181.97M | -$244.09M | -$111.53M | +25.4% |
| Investing cash flow | -$177.07M | -$627.87M | -$2.70B | +71.8% |
| Share buybacks | -$140.95M | -$745.72M | -$200.00M | +81.1% |
| Dividends paid | -$1.11B | -$163.95M | $0 | -576.8% |
| Financing cash flow | -$483.46M | -$279.19M | -$281.67M | -73.2% |
| Free cash flow | $458.98M | $310.33M | $459.38M | +47.9% |
| End cash position | $56.99M | $77.97M | $421.35M | -26.9% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
35.03
-3.33% from price
SMA 20
35.88
-5.59% from price
SMA 50
34.61
-2.13% from price
SMA 100
—
—
SMA 200
—
—
EMA 12
35.00
-3.23% from price
EMA 26
35.19
-3.75% from price
EMA 50
34.44
-1.67% from price
RSI (14)
42.5
Neutral
MACD (12,26,9)
-0.19
Hist -0.58
ATR (14)
1.33
3.94% of price
Realised vol 30D
43.6%
Annualised
Bollinger upper
38.53
20, 2σ
Bollinger lower
33.22
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Risk profile
Beta vs SPY
—
—
Correlation to SPY
—
—
Realised vol 30D
43.6%
Annualised
Market vol 1Y
—
SPY, annualised
Max drawdown 1Y
-15.8%
Peak to trough
Max drawdown 5Y
-15.8%
Peak to trough
ATR 14
1.33
3.94% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Jim Cramer Argued It’s A New World For Palo Alto Networks & CrowdStrike Holdings
Insider Monkey · 8m ago
Jim Cramer Dismissed Market Reaction To Cisco Systems, Inc. (NASDAQ:CSCO) Following Earnings
Insider Monkey · 11m ago
Jim Cramer Doesn’t Think Home Depot Is Expensive Enough To Be Avoided
Insider Monkey · 17m ago
Jim Cramer Advised Being Patient & Buying Walmart Inc. (NASDAQ:WMT)’s Shares
Insider Monkey · 18m ago
Jim Cramer Discussed Ross Stores, Inc. (NASDAQ:ROST) & TJX
Insider Monkey · 19m ago
Anthropic's Investors Want a $2 Trillion IPO. The Last Record-Setting IPO Has Made Its Buyers Nothing in Two Months.
Motley Fool · 20m ago
NIKE, Inc. (NYSE:NKE) Vs On Holding (NYSE:ONON) – Here’s What Jim Cramer Thinks
Insider Monkey · 22m ago
Jim Cramer Continued To Complain About JPMorgan Chase & Co. (NYSE:JPM) & Wells Fargo’s Multiple
Insider Monkey · 23m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.